551 related articles for article (PubMed ID: 21971424)
1. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
2. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA.
Lin PJ; Tam YY; Hafez I; Sandhu A; Chen S; Ciufolini MA; Nabi IR; Cullis PR
Nanomedicine; 2013 Feb; 9(2):233-46. PubMed ID: 22698807
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
4. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
5. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.
Bao Y; Jin Y; Chivukula P; Zhang J; Liu Y; Liu J; Clamme JP; Mahato RI; Ng D; Ying W; Wang Y; Yu L
Pharm Res; 2013 Feb; 30(2):342-51. PubMed ID: 22983644
[TBL] [Abstract][Full Text] [Related]
6. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
7. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells.
Ferraresso F; Strilchuk AW; Juang LJ; Poole LG; Luyendyk JP; Kastrup CJ
Mol Pharm; 2022 Jul; 19(7):2175-2182. PubMed ID: 35642083
[TBL] [Abstract][Full Text] [Related]
8. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
10. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
11.
Algarni A; Pilkington EH; Suys EJA; Al-Wassiti H; Pouton CW; Truong NP
Biomater Sci; 2022 May; 10(11):2940-2952. PubMed ID: 35475455
[TBL] [Abstract][Full Text] [Related]
12. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.
Tao W; Davide JP; Cai M; Zhang GJ; South VJ; Matter A; Ng B; Zhang Y; Sepp-Lorenzino L
Mol Ther; 2010 Sep; 18(9):1657-66. PubMed ID: 20628357
[TBL] [Abstract][Full Text] [Related]
15. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
[TBL] [Abstract][Full Text] [Related]
16. Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.
Tam YY; Chen S; Zaifman J; Tam YK; Lin PJ; Ansell S; Roberge M; Ciufolini MA; Cullis PR
Nanomedicine; 2013 Jul; 9(5):665-74. PubMed ID: 23219877
[TBL] [Abstract][Full Text] [Related]
17. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.
Jayaraman M; Ansell SM; Mui BL; Tam YK; Chen J; Du X; Butler D; Eltepu L; Matsuda S; Narayanannair JK; Rajeev KG; Hafez IM; Akinc A; Maier MA; Tracy MA; Cullis PR; Madden TD; Manoharan M; Hope MJ
Angew Chem Int Ed Engl; 2012 Aug; 51(34):8529-33. PubMed ID: 22782619
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanoparticles for short interfering RNA delivery.
Leung AK; Tam YY; Cullis PR
Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
[TBL] [Abstract][Full Text] [Related]
19. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
